ADAMTS13 Deficiency Worsens Colitis and Exogenous ADAMTS13 Administration Decreases Colitis Severity in Mice

Abstract Background Inflammatory bowel disease (IBD) affects 1.6 million people in the United States. IBD is associated with an increased risk of thrombosis, which rises with disease activity. The pathogenesis of IBD and its increased thrombotic risk is not completely understood. Ultra large von Willebrand factor (ULVWF) multimers are secreted from activated endothelium, leading to recruitment of platelets and leukocytes. A disintegrin and metalloproteinase with thrombospondin type I repeats motif 13 (ADAMTS13) cleaves highly adhesive ULVWF into smaller, less bioactive, multimers, releasing them into circulation. Mice deficient in ADAMTS13 (ADAMTS13−/−) have heightened inflammatory and thrombotic responses. Objectives We hypothesized that upon colitis induction, ADAMTS13−/− mice would have more severe symptoms compared with wild-type (WT) mice, and rhADAMTS13 administration to mice with colitis would improve their condition. Results Dextran sodium sulfate–induced colitis was worse in ADAMTS13−/− mice than WT. ADAMTS13−/− showed increased weight loss, worse anemia, and increased clinical and histologic colitis severity, compared with WT mice. ADAMTS13−/− mice had increased VWF release, with accumulation at inflamed colonic sites. Also, the majority of mice showed one or more submucosal colonic thrombi. ADAMTS13 deficiency worsened colitis and propagated intestinal inflammation, most likely through increased platelet–leukocyte recruitment by VWF. Treatment of WT mice with rhADAMTS13 decreased colitis severity without worsening anemia. Additionally, several immune-mediated chronic murine colitis models, and inflamed colon tissue specimens from IBD patients, showed increased VWF release at inflamed sites, suggesting a generalizability of our findings. Conclusion Measuring VWF/ADAMTS13 levels could have clinical utility. When applicable, the administration of ADAMTS13, in addition to primary treatment, may improve outcomes for IBD patients.

[1]  S. Lentz.  Thrombosis in the setting of obesity or inflammatory bowel disease. , 2016, Blood.

[2]  Graham M Lord,et al.  Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation , 2015, Gastroenterology.

[3]  H. Demirci,et al.  Pulse Wave Velocity, Intima Media Thickness, and Flow-mediated Dilatation in Patients with Normotensive Normoglycemic Inflammatory Bowel Disease , 2015, Inflammatory bowel diseases.

[4]  C. Hermans,et al.  The novel ADAMTS13‐p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice , 2015, Journal of thrombosis and haemostasis : JTH.

[5]  A. Schoepfer,et al.  Prevalence and clinical importance of mesenteric venous thrombosis in the Swiss Inflammatory Bowel Disease Cohort. , 2014, AJR. American journal of roentgenology.

[6]  C. Klein,et al.  Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. , 2014, Immunity.

[7]  D. Wagner,et al.  VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice. , 2014, Blood.

[8]  H. Tilg,et al.  Clinical presentation of venous thromboembolism in inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[9]  D. Wagner,et al.  Endothelial Von Willebrand Factor Promotes Blood–Brain Barrier Flexibility and Provides Protection From Hypoxia and Seizures in Mice , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[10]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[11]  E. Senchenkova,et al.  Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis. , 2013, The American journal of pathology.

[12]  E. Senchenkova,et al.  Platelet Abnormalities during Colonic Inflammation , 2013, Inflammatory bowel diseases.

[13]  A. Chauhan,et al.  ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. , 2012, Blood.

[14]  D. Wagner,et al.  Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. , 2012, Blood.

[15]  Michael D. Kappelman,et al.  Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially Insured US Population , 2012, Digestive Diseases and Sciences.

[16]  D. Motto,et al.  ADAMTS13 reduces VWF‐mediated acute inflammation following focal cerebral ischemia in mice , 2012, Journal of thrombosis and haemostasis : JTH.

[17]  B. Lämmle,et al.  von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. , 2011, Blood.

[18]  C. Trenor,et al.  Thrombosis and inflammatory bowel disease: A call for improved awareness and prevention , 2011, Inflammatory bowel diseases.

[19]  A. Zarbock,et al.  von Willebrand factor promotes leukocyte extravasation. , 2010, Blood.

[20]  C. Ha,et al.  Risk of Arterial Thrombotic Events in Inflammatory Bowel Disease , 2009, The American Journal of Gastroenterology.

[21]  A. Chauhan,et al.  The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. , 2009, Blood.

[22]  P. Alex,et al.  Distinct Cytokine Patterns Identified from Multiplex Profiles of Murine DSS and TNBS‐Induced Colitis , 2009, Inflammatory bowel diseases.

[23]  A. Chauhan,et al.  Abbreviations used: AD- , 2022 .

[24]  A. Chauhan,et al.  The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. , 2008, Blood.

[25]  C. Klein,et al.  Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient in Wiskott-Aldrich syndrome protein. , 2007, Gastroenterology.

[26]  M. Neurath,et al.  Mouse models of inflammatory bowel disease. , 2007, Advanced drug delivery reviews.

[27]  M. Cybulsky,et al.  Getting to the site of inflammation: the leukocyte adhesion cascade updated , 2007, Nature Reviews Immunology.

[28]  P. Mannucci,et al.  ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis , 2007, British journal of haematology.

[29]  R. Xavier,et al.  Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.

[30]  S. Danese,et al.  Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens , 2007, The American Journal of Gastroenterology.

[31]  C. Gahmberg,et al.  P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. , 2006, Blood.

[32]  E. Mizoguchi.  Chitinase 3-like-1 exacerbates intestinal inflammation by enhancing bacterial adhesion and invasion in colonic epithelial cells. , 2006, Gastroenterology.

[33]  N. Nikolaidis,et al.  Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation. , 2005, World journal of gastroenterology.

[34]  A. Chauhan,et al.  Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. , 2005, The Journal of clinical investigation.

[35]  J. Reimund,et al.  A comparative study of endothelial cell markers expressed in chronically inflamed human tissues: MECA‐79, Duffy antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146 , 2005, The Journal of pathology.

[36]  K. Stokes,et al.  Molecular determinants of the prothrombogenic phenotype assumed by inflamed colonic venules. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[37]  Shahid Ahmed,et al.  Correlation of thrombotic thrombocytopenic purpura disease activity with von Willibrand factor-cleaving protease level in ulcerative colitis. , 2004, The American journal of medicine.

[38]  Kazuo Fujikawa,et al.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. , 2002, Blood.

[39]  C. Bernstein,et al.  The Incidence of Deep Venous Thrombosis and Pulmonary Embolism among Patients with Inflammatory Bowel Disease: A Population-based Cohort Study , 2001, Thrombosis and Haemostasis.

[40]  Susan D. Spencer,et al.  The Orphan Receptor CRF2-4 Is an Essential Subunit of the Interleukin 10 Receptor , 1998, The Journal of experimental medicine.

[41]  T. Mayadas,et al.  Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. , 1996, The Journal of clinical investigation.

[42]  R. Pounder,et al.  Inherited disorders of coagulation appear to protect against inflammatory bowel disease. , 1995, Gastroenterology.

[43]  M. Hudson,et al.  Mucosal capillary thrombi in rectal biopsies , 1992, Histopathology.

[44]  D. Rampton,et al.  Circulating von Willebrand factor in inflammatory bowel disease. , 1992, Gut.

[45]  N. Oshitani,et al.  Possible role of vascular endothelial cells in immune responses in colonic mucosa examined immunocytochemically in subjects with and without ulcerative colitis. , 1989, Clinical and experimental immunology.

[46]  D. Wagner,et al.  VON WILLEBRAND FACTOR RELEASED FROM WEIBEL-PALADE BODIES BINDS MORE AVIDLY TO EXTRACELLULAR MATRIX THAN THAT SECRETED CONSTITUTIVELY , 1987, Thrombosis and Haemostasis.

[47]  A. Harries,et al.  Platelet count: a simple measure of activity in Crohn's disease. , 1983, British medical journal.

[48]  C. Esmon.  The impact of the inflammatory response on coagulation. , 2004, Thrombosis research.

[49]  S. Burstein.  Cytokines, platelet production and hemostasis. , 1997, Platelets.

[50]  D. Wagner.  Cell biology of von Willebrand factor. , 1990, Annual review of cell biology.